Research Article
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
| | Study (Reference) | Number of patients (ID/C) | Comparator | Trial duration
(wks) | Age (ys) | Duration of DM (ys) | BMI Baseline
(Kg/m2) | BMI at 6-month (Kg/m2) | HbA1c
baseline (%) | HbA1c at 6-month
(%, ID/C) |
| | Liraglutide | | | | | | | | | | | Marre et al. [21] | 234/114 | Placebo | 26 | 56 | 7.0 | 30.0 | 29.9/30.3 | 8.5 | 7.5/8.7 | | Nauck et al. [22] | 242/121 | Placebo | 26 | 57 | 8.0 | 31.3 | 30.1/31.1 | 8.3 | 7.3/8.5 | | Zinman et al. [23] | 355/175 | Placebo | 26 | 55 | 9.0 | 33.5 | 33.0/33.7 | 8.5 | 7.0/7.9 | | Russell-Jones et al. [24] | 230/114 | Placebo | 26 | 57 | 9.0 | 30.9 | 29.9/31.2 | 8.3 | 7.0/8.1 | | Nauck et al. [22]# | 242/242 | Glimepiride | 26 | 57 | 8.0 | 31.1 | 30.1/31.6 | 8.3 | 7.3/7.4 | | Garber et al. [25] | 498/248 | Glimepiride | 52 | 53 | 5.0 | 33.0 | 32.3/33.6 | 8.3 | 7.1/7.8 | | Marre et al. [21]# | 234/232 | Rosiglitazone | 26 | 56 | 7.0 | 29.8 | 29.9/30.2 | 8.4 | 7.5/8.1 | | Pratley et al. [26] | 225/219 | Sitagliptin | 52 | 55 | 6.0 | 32.8 | 29.9/31.5 | 8.4 | 6.9/7.3 | | Russell-Jones et al. [27] # | 230/232 | Glargine | 26 | 57 | 9.0 | 30.3 | 29.9/30.9 | 8.3 | 7.0/7.2 |
| | Exenatide LAR | | | | | | | | | | | Diamant et al. [27] | 233/233 | Glargine | 26 | 58 | 8.0 | 32.0 | 31.1/32.5 | 8.3 | 6.8/7.0 | | Bergenstal et al. [28] | 160/165 | Pioglitazone | 26 | 52 | 6.0 | 32.0 | 31.2/33.0 | 8.5 | 7.2/7.4 | | Bergenstal et al. [28]# | 160/166 | Sitagliptin | 26 | 52 | 6.0 | 32.0 | 31.2/31.7 | 8.5 | 7.2/7.7 |
| | Exenatide | | | | | | | | | | | Obesity | | | | | | | | | | | Rosenstock et al. [15] | 73/79 | Placebo | 24 | 46 | 0.0 | 39.5 | 37.8/38.8 | 5.6 | 5.6/5.7 | | Elkind-Hirsch et al. [20] | 20/20 | Placebo | 24 | 29 | 0.0 | 40.4 | 39.1/40.8 | NR | NR/NR | | Type 2 diabetes | | | | | | | | | | | Moretto et al. [29] | 77/78 | Placebo | 24 | 54 | 2.0 | 31.5 | 30.4/31.4 | 7.8 | 6.9/7.6 | | Buse et al. [30] | 129/123 | Placebo | 30 | 55 | 6.3 | 33.3 | 32.4/33.8 | 8.6 | 7.8/8.7 | | Buse et al. [31] | 138/123 | Placebo | 30 | 59 | 12.0 | 33.5 | 33.2/33.5 | 8.4 | 6.6/7.5 | | Kendall et al. [19] | 241/247 | Placebo | 30 | 55 | 9.0 | 34.0 | 32.9/33.7 | 8.5 | 7.7/8.6 | | DeFronzo et al. [32] | 113/113 | Placebo | 30 | 53 | 5.8 | 34.0 | 33.0/33.9 | 8.2 | 7.4/8.3 | | Derosa et al. [33] | 61/62 | Glibenclamide | 52 | 56 | NR | 28.6 | 27.3/28.9 | 8.8 | 8.1/8.0 | | Derosa et al. [34] | 57/54 | Glimepiride | 52 | 55 | NR | 28.4 | 27.5/28.5 | 8.7 | 7.9/8.1 | | Gallwitz et al. [35] | 248/246 | BiAsp | 26 | 57 | 5.0 | 33.1 | 32.0/33.2 | 7.9 | 6.9/6.8 | | Nauck et al. [36] | 253/248 | BiAsp | 52 | 59 | 9.9 | 30.4 | 29.9/30.5 | 8.6 | 7.5/7.6 | | Heine et al. [37] | 282/267 | Glargine | 26 | 59 | 9.5 | 31.3 | 30.6/32.0 | 8.2 | 7.2/7.1 | | Bunck et al. [38] | 36/33 | Glargine | 52 | 58 | 5.0 | 30.5 | 29.9/30.4 | 7.5 | 6.7/6.8 |
|
|
#Studies with multiple comparators; NR: not reported; ID: interventional drug; C: comparator; DM: diabetes mellitus; wks: weeks.
|
